Table 1

 Characteristics of the 548 patients with culture confirmed tuberculosis

CharacteristicEmpirical antibiotic use
FQ(n = 79)Others(n = 218)No antibiotic(n = 251)
AFS, acid fast smear; AIDS, acquired immunodeficiency syndrome; CNS, central nervous system; CXR, chest radiograph; PTB, pulmonary tuberculosis; TB, tuberculosis.
*Chronic renal insufficiency was defined as a serum creatinine level >20 mg/l.12
†p<0.05 FQ group v no antibiotic group.
‡p<0.05 other antibiotic group v no antibiotic group.
¶p<0.05 FQ group v other antibiotic group.
Age >65 years42 (53.2%)†133 (61.0%)‡79 (31.5%)
Male sex49 (62.0%)150 (68.8%)163 (64.9%)
Underlying disease42 (53.2%)†102 (46.8%)‡86 (34.3%)
    Diabetes mellitus20 (25.3%)51 (23.4%)50 (19.9%)
    Malignancy13 (16.5%)29 (13.3%)24 (9.6%)
    Chronic renal insufficiency*8 (10.1%)30 (13.8%)7 (2.8%)
    Receiving steroid5 (6.3%)6 (2.8%)11 (4.4%)
    AIDS5 (6.3%)10 (4.6%)5 (2.0%)
    Liver cirrhosis2 (2.5%)5 (2.3%)6 (2.4%)
    Alcoholism01 (0.5%)3 (1.2%)
Smoking
    Current smoker17 (21.5%)62 (28.4%)72 (28.3%)
    Ex-smoker14 (17.7%)27 (12.4%)25 (10.0%)
Extrapulmonary TB20 (25.3%)72 (33.0%)‡43 (17.1%)
    TB pleurisy or peritonitis11 (13.9%)43 (19.7%)22 (8.8%)
    Musculoskeletal TB4 (5.1%)9 (4.1%)7 (2.8%)
    TB lymphadenopathy0 (0%)6 (2.8%)8 (3.2%)
    Urogenital TB1 (1.3%)10 (4.6%)3 (1.2%)
    TB meningitis1 (1.3%)1 (0.5%)3 (1.2%)
    Disseminated TB3 (3.8%)3 (1.4%)0
Symptom at presentation
    Respiratory symptoms52 (65.8%)127 (58.3%)‡177 (70.5%)
    Constitutional symptoms41 (51.9%)†103 (47.2%)‡60 (23.9%)
    CNS symptoms4 (5.1%)14 (6.4%)7 (2.8%)
    Neck mass05 (2.3%)6 (2.4%)
    Dysuria03 (1.4%)2 (0.8%)
    Musculoskeletal symptoms2 (2.5%)5 (2.3%)6 (2.4%)
    Abdominal symptoms2 (2.5%)10 (4.6%)8 (3.2%)
    None (incidental finding)4 (5.1%)17 (7.8%)29 (11.6%)
Symptom >14 days46 (58.2%)†122 (56.0%)‡193 (76.9%)
Ordering CXR at initial visit in PTB69 (87.3%)174 (79.8%)194 (77.3%)
CXR finding
    Pattern
    Fibronodular infiltrates25 (31.6%)66 (30.3%)84 (33.5%)
    Alveolar consolidation33 (41.8%)86 (39.4%)77 (30.7%)
    Multiple nodules or mass9 (11.4%)20 (9.2%)44 (17.5%)
    Fibrotic change5 (6.3%)15 (6.9%)12 (4.8%)
    Miliary shadowing1 (1.3%)8 (3.7%)10 (4.0%)
    No parenchymal lesion6 (7.6%)23 (10.6%)24 (9.6%)
    Lower lung field TB18 (22.8%)47 (21.6%)‡36 (14.3%)
    Cavity9 (11.4%)21 (9.6%)‡43 (17.1%)
Albumin (g/dl)
    <35/⩾3543 (67.2%)/21†113 (64.9%)/61‡54 (35.1%)/100
    Mean (SD)31.7 (6.2)†32.2 (6.1)‡37.4 (6.4)
Sputum AFS+ in PTB8 (12.1%)†¶53 (24.3%)65 (25.9%)
Single drug resistance20 (25.3%)48 (22.0%)73 (29.1%)
Multidrug resistance10 (12.7%)17 (7.8%)29 (11.6%)